Were Compass Pathways' Clinical Trial Results Really That Bad?
Compass Pathways (NASDAQ: CMPS) has released data for a phase 2b study of its COMP360 psilocybin treatment for depression. In this Motley Fool Live video recorded on November 15, Motley Fool contributors Keith Speights and Brian Orelli point out that the therapy helped reduce patients' depression symptoms, but the drug's effectiveness seemed to wane over time and adverse effects were seen in patients taking higher doses.
However, the company still has the potential to make improvements to the drug, and will likely have significant flexibility with the FDA in the eventual approval process since the drug is targeting treatment-resistant depression where patients have no other options.
Source Fool.com
